Cassava Sciences Crecimiento futuro

Future controles de criterios 3/6

Cassava Sciences se prevé un crecimiento anual de los beneficios y los ingresos de 104.9% y 149.8%, respectivamente, mientras que el BPA aumentará de grow a 99.6%.

Información clave

104.9%

Tasa de crecimiento de los beneficios

99.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	20.9%
Tasa de crecimiento de los ingresos	149.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	12 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Jul 27

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Jun 10

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

May 31

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Apr 19

3 Key Points To Remember About Cassava Sciences

Apr 07

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Mar 31

Cassava Sciences: Why The Stock Is Rangebound

Feb 28

The FDA Deals Another Blow To Cassava Sciences' Bears

Feb 11

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

Feb 02

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Jan 17

Cassava Sciences, Inc. - The Short Squeeze Has Started

Jan 06

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Dec 30

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Dec 28

Cassava Sciences Stock: Here We Go Again

Dec 21

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

Dec 02

Cassava Sciences Gets Underway Putting Simufilam To The Test

Nov 24

Cassava Sciences: Data Rules!

Nov 17

Cassava Sciences' Hypothesis Raises Doubts

Nov 08

Cassava Sciences Stock: Massive Potential Marred By Controversy

Nov 01

Cassava Sciences: Welcome To The Casino

Oct 25

Has Cassava Sciences Put Out The Fire For Now?

Sep 28

Cassava Sciences: Medical History In The Making

Sep 21

Cassava Sciences: One Doubtful Drug For One Doubtful Indication

Sep 15

We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth

Sep 14

More On Cassava Sciences' Controversy

Sep 04

Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor

Aug 26

5 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market

Jul 27

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:SAVA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	300	120	N/A	N/A	1
12/31/2024	N/A	-93	N/A	N/A	1
12/31/2023	N/A	-97	-82	-82	N/A
9/30/2023	N/A	-95	-81	-81	N/A
6/30/2023	N/A	-90	-77	-76	N/A
3/31/2023	N/A	-83	-70	-67	N/A
12/31/2022	N/A	-76	-80	-78	N/A
9/30/2022	N/A	-71	-67	-64	N/A
6/30/2022	N/A	-61	-81	-57	N/A
3/31/2022	N/A	-46	-74	-51	N/A
12/31/2021	N/A	-32	-52	-30	N/A
9/30/2021	N/A	-21	-45	-23	N/A
6/30/2021	N/A	-13	-11	-11	N/A
3/31/2021	N/A	-9	-6	-6	N/A
12/31/2020	N/A	-6	-5	-5	N/A
9/30/2020	N/A	-5	-5	-5	N/A
6/30/2020	N/A	-4	-3	-3	N/A
3/31/2020	N/A	-4	-3	-3	N/A
12/31/2019	N/A	-5	-3	-3	N/A
9/30/2019	N/A	-4	-3	-2	N/A
6/30/2019	N/A	-4	-3	-3	N/A
3/31/2019	N/A	-6	-4	-4	N/A
12/31/2018	N/A	-7	-5	-5	N/A
9/30/2018	N/A	-8	-6	-6	N/A
6/30/2018	N/A	-10	-6	-6	N/A
3/31/2018	N/A	-11	-8	-8	N/A
12/31/2017	N/A	-12	-8	-8	N/A
9/30/2017	N/A	-12	N/A	-10	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-12	N/A	-11	N/A
12/31/2016	N/A	-15	N/A	-12	N/A
9/30/2016	N/A	-17	N/A	-13	N/A
6/30/2016	N/A	-17	N/A	-12	N/A
3/31/2016	N/A	-17	N/A	-11	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A
6/30/2015	N/A	-12	N/A	-7	N/A
3/31/2015	N/A	-12	N/A	-8	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
9/30/2014	35	23	N/A	-8	N/A
6/30/2014	37	26	N/A	-9	N/A
3/31/2014	39	29	N/A	-8	N/A
12/31/2013	41	32	N/A	-7	N/A
9/30/2013	8	-3	N/A	-7	N/A
6/30/2013	9	-4	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: SAVA se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: SAVA se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: SAVA se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: SAVA no tendrá ingresos el año que viene.

Ingresos de alto crecimiento: SAVA no tendrá ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de SAVA se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Cassava Sciences Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$0.77 loss

Forecast to breakeven in 2023

Price target increased to US$84.00

Price target decreased to US$58.67

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Recent updates

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia

Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index

Cassava Sciences, Inc. Announces Board Appointments

New major risk - Revenue and earnings growth

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease

Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease

Independent Director recently bought US$308k worth of stock

New major risk - Revenue and earnings growth

Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging

Founder exercised options and sold US$480k worth of stock

Lead Independent Director exercised options to buy US$259k worth of stock.

Independent Director recently bought US$2.3m worth of stock

Consensus EPS estimates upgraded to US$0.77 loss

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Forecast to breakeven in 2023

Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Price target increased to US$84.00

Cassava Sciences, Inc. Announces Executive Changes

Cassava Sciences, Inc. Announces Completion of Dosing in Open-Label Study of Simufilam for Alzheimer’s Disease

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences, Inc. Appoints Christopher Cook as Senior Vice President and General Counsel

Cassava Sciences Announces Initiation of an Open-Label Extension Study

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Cassava Sciences: Trying To Manage Expectations

Lead Independent Director exercised options to buy US$86k worth of stock.

Cassava Sciences reaches over five-month high on rising volumes

Cassava Sciences Looks As Good Of A Purchase As Ever

Cassava Sciences stock jumps 10% after director buys $860K shares

Chief Clinical Development Officer recently bought US$61k worth of stock

Lead Independent Director recently bought US$2.1m worth of stock

Cassava Sciences rally continues as stock up 39%

Price target decreased to US$58.67

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Founder exercised options and sold US$249k worth of stock

Chief Medical Officer & Director exercised options and sold US$81k worth of stock

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

Founder exercised options to buy US$1.0m worth of stock.

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Lead Independent Director exercised options to buy US$180k worth of stock.

Forecast to breakeven in 2022

Cassava Sciences: Why The Stock Is Rangebound

The FDA Deals Another Blow To Cassava Sciences' Bears

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Cassava Sciences, Inc. - The Short Squeeze Has Started

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Cassava Sciences Stock: Here We Go Again

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

Cassava Sciences Gets Underway Putting Simufilam To The Test

Cassava Sciences: Data Rules!